Skip to content

Electrostimulation Study for Ocular Graft vs. Host Disease

Pilot Trial of Non-invasive Electrostimulation in Chronic Ocular Graft-vs-Host Disease

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07166848
Enrollment
15
Registered
2025-09-10
Start date
2025-11-30
Completion date
2029-11-30
Last updated
2026-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Ocular Graft-versus-host Disease

Keywords

GVHD, Electrostimulation

Brief summary

This trial is testing to see if electrostimulation treatment (ET) will be effective in treating those with ocular Graft vs. Host Disease.

Detailed description

The trial is to test whether transcutaneous electrical stimulation (TES) may be an effective new type of non-invasive treatment for patients who are diagnosed with chronic ocular Graft-vs-Host Disease. Such a treatment can potentially decrease the need for the patients to apply eye drops frequently, repair the damage caused by chronic ocular Graft-vs-Host Disease, and improve the comfort of the eyes naturally.

Interventions

DEVICEElectrodes with Currents

Electrodes will be placed on the cheeks and forehead, and treated with an amplitude of 300 µA for 30 mins

DEVICEElectrodes without Currents

Electrodes will be placed on the cheeks and forehead, and treated with an no amplitude for 30 mins

Sponsors

Zhonghui K. Luo, MD, PhD
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

The principal investigator and the participants will be masked to treatment. The study staff setting up the device will be the only staff who will know the randomization.

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of chronic ocular graft vs. host disease (oGVHD) (ICCGVHD criteria probable or definite) * OSDI score of 22 or higher * NEI corneal staining score (or modified NEI score) of 2 or higher.

Exclusion criteria

* Patients with any open wound on the eyelid. * Patient with any active cornea ulcer, dacryocystitis, hordeolum, filamentary keratitis, uveitis, retinal detachment, uncontrolled glaucoma or other active pathology per PI's discretion. * Patient with a pacemaker or ICD. * Patient currently pregnant or with a potential to be pregnant during the study. * Patient undergoing any ocular surgical procedure (including intravitreal injections) within the past 3 months. * Patient undergoing any systemic surgical procedures within 2 months. * Patient undergoing any non-surgical eyelid procedure such as punctal plugs or punctal cautery within 1 month of study initiation. * Patients on cytotoxic agents, drugs that inhibit peripheral nerve regeneration (i.e. Gabapentin, Nicotine), radiation therapy, or any other therapy per PI's discretion. * Patients undergoing immunosuppression regimen change within 1 month of study initiation and/or during the study period. * Patient who wears contact lens of any kind

Design outcomes

Primary

MeasureTime frameDescription
Efficacy of Electrostimulation (ES) Treatment.8 WeeksTo evaluate whether the use of electrostimulation (ES) over a course of 10 treatments (in 8 weeks) will ameliorate symptoms and signs of chronic ocular Graft-vs-Host Disease (oGVHD) and the effect on sub-basal corneal nerve regeneration.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORZhonghui Luo, MD, PhD

Massachusetts Eye and Ear Infirmary

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 22, 2026